The U.S. Food and Drug Administration (FDA) has approved the diabetes drug Mounjaro for broader use, now including reducing the risk of major cardiovascular events. Originally approved for type 2 diabetes, the expanded approval is based on clinical trial results demonstrating a significant reduction in cardiovascular events like heart attack, stroke, and death in adult patients with type 2 diabetes and established cardiovascular disease. Mounjaro, manufactured by Eli Lilly, works by mimicking a naturally occurring hormone that regulates blood sugar and aids in weight loss. This approval marks a significant step in addressing the substantial cardiovascular risks faced by individuals with type 2 diabetes. Doctors anticipate this will become a crucial treatment option for a high-risk patient population. The FDA emphasized the importance of considering cardiovascular risk when managing diabetes, and this approval reflects that understanding.